Avanos Medical (NYSE:AVNS - Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 1.300-1.450 for the period, compared to the consensus estimate of 1.380. The company issued revenue guidance of $685.0 million-$705.0 million, compared to the consensus revenue estimate of $691.0 million.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded Avanos Medical from a buy rating to a hold rating in a research note on Friday.
Read Our Latest Analysis on Avanos Medical
Avanos Medical Stock Performance
AVNS stock traded down $0.02 during trading hours on Friday, reaching $19.69. The stock had a trading volume of 245,744 shares, compared to its average volume of 278,542. The stock has a market capitalization of $909.68 million, a PE ratio of -14.92 and a beta of 0.97. The stock has a 50-day simple moving average of $19.19 and a 200 day simple moving average of $19.90. Avanos Medical has a fifty-two week low of $17.24 and a fifty-two week high of $26.56. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.08 and a quick ratio of 1.38.
Avanos Medical (NYSE:AVNS - Get Free Report) last issued its earnings results on Tuesday, February 20th. The company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.01). The firm had revenue of $173.30 million during the quarter, compared to analyst estimates of $170.43 million. Avanos Medical had a negative net margin of 8.76% and a positive return on equity of 4.25%. The company's revenue for the quarter was down 4.6% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Analysts predict that Avanos Medical will post 1.38 EPS for the current fiscal year.
Insider Activity at Avanos Medical
In other Avanos Medical news, CFO Michael Greiner sold 8,000 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $19.12, for a total value of $152,960.00. Following the transaction, the chief financial officer now directly owns 151,495 shares in the company, valued at $2,896,584.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.90% of the stock is owned by company insiders.
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Read More
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
